Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Other hematologic neoplasm 2Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2

Interventions

Fulvestrant 85Letrozole 79Paclitaxel 76pembrolizumab 72Specimen Handling 67Trastuzumab 62Carboplatin 57Magnetic Resonance Spectroscopy 52ribociclib 49Capecitabine 49Anastrozole 48pertuzumab 46palbociclib 45abemaciclib 41exemestane 40Tamoxifen 40Cyclophosphamide 40Biopsy 39trastuzumab deruxtecan 31Docetaxel 30Radiotherapy 29Taxes 28Gemcitabine 25Blood Specimen Collection 25130-nm albumin-bound paclitaxel 25Surveys and Questionnaires 23olaparib 22Standard of Care 22sacituzumab govitecan 20eribulin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
axatilimab × Breast × 90 days × Clear all
NCT06959537 2026-05-20

A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

M.D. Anderson Cancer Center

Phase 1 Recruiting
24 enrolled
Breast

Breast Neoplasms

NCT05491226 2026-04-20

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Cedars-Sinai Medical Center

Phase 2 Recruiting
35 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07015853 2026-04-20

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

Cedars-Sinai Medical Center

Phase 2 Not yet recruiting
34 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡